Pat O’Sullivan
Chief Operating Officer presso AMICUS THERAPEUTICS, INC.
Profilo
Pat O’Sullivan currently works at Amicus Therapeutics, Inc., as Chief Technical Operations Officer from 2022.
Mr. O’Sullivan also formerly worked at Genzyme Therapeutics Ltd., as Vice President-Global Supply Chain from 2001 to 2022.
Mr. O’Sullivan received his Masters Business Admin degree from The Open University and undergraduate degree from Munster Technological University.
Posizioni attive di Pat O’Sullivan
| Società | Posizione | Inizio |
|---|---|---|
| AMICUS THERAPEUTICS, INC. | Chief Operating Officer | 01/07/2022 |
Precedenti posizioni note di Pat O’Sullivan
| Società | Posizione | Fine |
|---|---|---|
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | 01/08/2022 |
Formazione di Pat O’Sullivan
| The Open University | Masters Business Admin |
| Munster Technological University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| AMICUS THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Pat O’Sullivan
